OasisLMS

In this special WCLC 2025 episode of Lung Cancer Considered, hosts Dr. Narjust Florez and Dr. Stephen Liu discuss highlights from the conference.

Dr. Susan Scott discusses EGFR mutant NSCLC and results from PALOMA-2 and subcutaneous amivantamab. Dr. Wenfeng Fang discusses Iza-Bren (BL-D01D1), a first-in-class EGFR x HER-3 biospecific ADC linked to a novel topoisomerase I inhibitor payload, with promising preliminary activity in EGFR-positive, previously treated NSCLC.  

Dr. Biagio Ricciuti shares his insights from WCLC 2025, including the FLAURA-2 OS readout, the HARMONi trial in EGFR-positive NSCLC, and his research in the use of immunotherapy in early-stage lung cancer.

• Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, Boston, MA, USA  
• Stephen Liu, MD, Associate Professor of Medicine, Director of Thoracic Oncology and Director of Developmental Therapeutics, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C., USA 

Podcast Guests: 

• Wenfeng Fang, MD, PhD, Medical Oncologist, Sun Yat-sen University Cancer Center, Guangzhou, China
• Biagio Ricciuti, MD, PhD, Thoracic Medical Oncologist and Data Scientist, Dana-Farber Cancer Institute, Faculty, Harvard Medical School, Boston, MA, USA
• Susan Scott, MD, Medical Oncologist, Assistant Professor of Oncology, Johns Hopkins School of Medicine, Baltimore, MD, USA